Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells

被引:0
|
作者
Lee, Keun-Wook
Kim, Jee Hyun
Park, Jung-Hyun
Kim, Hwang-Phill
Song, Sang-Hyun
Kim, Sang Gyun
Kim, Tai Young
Jong, Hyun-Soon
Jung, Kyung Hae
Im, Seock-Ah
Kim, Tae-You
Kim, Noe Kyeong
Bang, Yung-Jue
机构
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea
[2] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110744, South Korea
[3] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Songnam, South Korea
[4] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[5] Natl Canc Ctr, Res Inst Hosp, Goyang 411769, Gyeonggi, South Korea
关键词
SK-7041; histone deacetylase inhibitor; lung cancer; breast cancer; apoptosis;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: A class of synthetic histone deacetylase (HDAC) inhibitors, which are hybrids of trichostatin A and MS-275 were previously developed. In this study, the antitumor effects of SK-7041, one of those novel HDAC inhibitors, was evaluated on lung and breast cancer cell lines. Materials and Methods: Human lung and breast cancer cells, as well as normal human bronchial epithelial (NHBE) cells were treated with SK-7041, and results were compared with those of cells treated with suberoylanilide hydroxamic acid (SAHA). Results: SK-7041 induced time-dependent histone hyperacetylation and showed more potent cytotoxicity than SAHA in cancer cells. These antiproliferative effects of SK-7041 were due to apoptotic cell death caused by G21M-phase arrest and to a lesser extent to G1 arrest. Moreover, SK-7041 inhibited cancer cell proliferation more selectively than NHBE cell proliferation. Conclusion: These results suggest that SK-7041 may have potential anticancer activity.
引用
收藏
页码:3429 / 3438
页数:10
相关论文
共 50 条
  • [31] The antitumor effects of OSU-HDAC42, a novel histone deacetylase inhibitor, in HER-2-positive breast cancer
    Weng, S.
    Wu, E.
    Kulp, S. K.
    Wang, D.
    Chen, C.
    Yee, L. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Histone deacetylase inhibition and estrogen signalling in human breast cancer cells
    Margueron, R
    Duong, V
    Castet, A
    Cavaillès, V
    BIOCHEMICAL PHARMACOLOGY, 2004, 68 (06) : 1239 - 1246
  • [33] Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells
    Janyst, Karolina
    Janyst, Michal
    Siernicka, Marta
    Lasek, Witold
    ONCOLOGY REPORTS, 2018, 39 (04) : 1999 - 2005
  • [34] Histone deacetylase inhibitors abrogate the levels and activity of estrogen receptor (ER) α and histone deacetylase (HDAC) 6 in human breast cancer cells (BCCs)
    Fiskus, W.
    Mohapatra, A.
    Bali, P.
    Balasis, M.
    Rao, R.
    Atadja, P.
    Wu, J.
    Bhalla, K.
    EJC SUPPLEMENTS, 2006, 4 (12): : 177 - 177
  • [35] Design, synthesis and antiproliferative activity of raloxifene/histone deacetylase inhibitor hybrids in breast cancer
    Wang, Yufei
    Sauvage, Madline
    Diennet, Marine
    Weber, Sandra
    Mader, Sylvie
    Gleason, James L.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 274
  • [36] Discovery of PAT-1102, a Novel, Potent and Orally Active Histone Deacetylase Inhibitor with Antitumor Activity in Cancer Mouse Models
    Hiriyan, Jagadheshan
    Shivarudraiah, Prasad
    Gavara, Govindarajulu
    Annamalai, Pazhanimuthu
    Natesan, Selvakumar
    Sambasivam, Ganesh
    Sukumaran, Sunil K.
    ANTICANCER RESEARCH, 2015, 35 (01) : 229 - 237
  • [37] Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor
    Le Tourneau, Christophe
    Siu, Lillian L.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (08) : 1247 - 1254
  • [38] CRA-024781:: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo
    Buggy, Joseph J.
    Cao, Z. Alexander
    Bass, Kathryn E.
    Verner, Erik
    Balasubramanian, Sriram
    Liu, Liang
    Schultz, Brian E.
    Young, Peter R.
    Dalrymple, Stacie A.
    MOLECULAR CANCER THERAPEUTICS, 2006, 5 (05) : 1309 - 1317
  • [39] Therapeutic Effect of Histone Deacetylase Inhibitor Panobinostat on Human Esophageal Cancer Cells
    Chen, Y.
    Chi, C.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S546 - S547
  • [40] Ras-increased susceptibility of human cancer cells to histone deacetylase inhibitor
    Choudhary, Shambhunath
    Chen, Yongfang
    Wang, Hwa-Chain R.
    CANCER RESEARCH, 2006, 66 (08)